title: Fingolimod. Mitsubishi Pharma/Novartis.
abstract: Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.
authors.affiliation: Francisj_dumont@yahoo.com
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Dumont
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical / Q000379:methods; D000068876:Fingolimod Hydrochloride; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D011409:Propylene Glycols / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine